作者：
Bradley, Mark [1]
;
Taylor, Rachel [2]
;
Jacobson, Julie [3]
;
Guex, Morgane [4]
;
Hopkins, Adrian [5]
;
Jensen, Julie [6]
;
Leonard, Lynn [7]
;
Waltz, Johannes [8]
;
Kuykens, Luc [9]
;
Sow, Papa Salif [10]
;
Madeja, Ulrich-Dietmar [11]
;
Hida, Takayuki [12]
;
Ole-Moiyoi, Kileken [13]
;
King, Jonathan [14]
;
Argaw, Daniel [15]
;
Mohamed, Jamsheed [16]
;
Polo, Maria Rebollo [17]
;
Yajima, Aya [18]
;
Ottesen, Eric
作者单位：
Pfizer Inc, Global Hlth & Patient Access, New York, NY USA
[1]
Task Force Global Hlth Atlanta, NTD Support Ctr, Atlanta, GA USA
[2]
Bridges Dev, Washington, DC USA
[3]
Int Federat Pharmaceut Manufacturers & Assoc, Geneva, Switzerland
[4]
Adrian Hopkins Consulting, Gravesend, Kent, England
[5]
Novartis Global Hlth & Corp Responsibil, Basel, Switzerland
[6]
Johnson & Johnson Global Publ Hlth, New Brunswick, NJ USA
[7]
Sanofi, Global Hlth Programs, Paris, France
[8]
Merck & Co Inc, Corp Responsibil, Kenilworth, NJ USA
[9]
WHO Geneva, Dept Control Neglected Trop Dis, Geneva, Switzerland
[10]
WHO Reg Off Western Pacific, Div Programs Dis Control, Manila, Philippines
[11]
Bayer AG Pharmaceut, Neglected Trop Dis Programs, Berlin, Germany
[12]
Grp Corp Affairs Merck KGaA, Global Hlth, Darmstadt, Germany
[13]
Eisai & Co Ltd, Sustainabil, Tokyo, Japan
[14]
GSK, Global Hlth, Brentford, England
[15]
Gilead Sci, Global Patient Solut Africa, Foster City, CA USA
[16]
WHO Reg Off South East Asia, Dept Communicable Dis, Delhi, India
[17]
WHO Reg Off Africa, Expanded Special Project Eliminat NTDs ESPEN, Brazzaville, Rep Congo
[18]
发布时间
2021-07-24
换一批
换一批
